TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07154368: A Randomized, Open-Label, Multicenter, Phase 3 Study Evaluating the Efficacy and Safety of JYP0322 Versus Platinum-Based Chemotherapy in ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer Patients Pr

Sponsor: Guangzhou JOYO Pharma Co., Ltd · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 207 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$20,993,280

Rescue Site Savings

+$13,842,444

Unlock Full NCT07154368 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07154368 Rescue Dossier →